Jonathan Chang
Stock Analyst at Leerink Partners
(0.93)
# 2,764
Out of 4,412 analysts
83
Total ratings
32.39%
Success rate
-16.26%
Average return
Main Sectors:
Top Industries:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBTX Nanobiotix | Initiates: Outperform | $11 | $5.81 | +89.33% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $12.80 | +298.44% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $6 → $5 | $1.10 | +354.55% | 10 | Jan 10, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $34 | $6.58 | +416.72% | 9 | Dec 7, 2022 | |
| FUSN Fusion Pharmaceuticals | Initiates: Outperform | $6 | $21.40 | -71.96% | 1 | Nov 30, 2022 | |
| CALA Calithera Biosciences | Downgrades: Market Perform | $18 → $2 | $0.02 | +9,900.00% | 5 | Nov 15, 2022 | |
| GMAB Genmab | Maintains: Market Perform | $31 → $33 | $28.57 | +15.51% | 9 | Nov 10, 2022 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $23.41 | +113.58% | 4 | Aug 22, 2022 | |
| VINC Vincerx Pharma | Maintains: Outperform | $6 → $5 | $0.84 | +495.17% | 5 | Aug 12, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $37.11 | -19.16% | 3 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $14.82 | -19.03% | 5 | Aug 9, 2022 | |
| MRSN Mersana Therapeutics | Maintains: Outperform | $13 → $14 | $3.16 | +343.04% | 5 | Aug 9, 2022 | |
| IMTX Immatics | Maintains: Outperform | $25 → $26 | $9.98 | +160.52% | 5 | Jun 3, 2022 | |
| ZLAB Zai Lab | Maintains: Outperform | $101 → $95 | $16.12 | +489.33% | 8 | May 11, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Market Perform | $2 → $3 | $1.15 | +160.87% | 6 | May 9, 2022 | |
| KURA Kura Oncology | Maintains: Outperform | $41 → $28 | $20.06 | +39.58% | 3 | Feb 25, 2022 | |
| XNCR Xencor | Maintains: Outperform | n/a | $21.07 | - | 3 | Aug 5, 2021 |
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $5.81
Upside: +89.33%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $12.80
Upside: +298.44%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $6 → $5
Current: $1.10
Upside: +354.55%
Replimune Group
Dec 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $6.58
Upside: +416.72%
Fusion Pharmaceuticals
Nov 30, 2022
Initiates: Outperform
Price Target: $6
Current: $21.40
Upside: -71.96%
Calithera Biosciences
Nov 15, 2022
Downgrades: Market Perform
Price Target: $18 → $2
Current: $0.02
Upside: +9,900.00%
Genmab
Nov 10, 2022
Maintains: Market Perform
Price Target: $31 → $33
Current: $28.57
Upside: +15.51%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $23.41
Upside: +113.58%
Vincerx Pharma
Aug 12, 2022
Maintains: Outperform
Price Target: $6 → $5
Current: $0.84
Upside: +495.17%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $37.11
Upside: -19.16%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $14.82
Upside: -19.03%
Mersana Therapeutics
Aug 9, 2022
Maintains: Outperform
Price Target: $13 → $14
Current: $3.16
Upside: +343.04%
Immatics
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $9.98
Upside: +160.52%
Zai Lab
May 11, 2022
Maintains: Outperform
Price Target: $101 → $95
Current: $16.12
Upside: +489.33%
Adaptimmune Therapeutics
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $1.15
Upside: +160.87%
Kura Oncology
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $20.06
Upside: +39.58%
Xencor
Aug 5, 2021
Maintains: Outperform
Price Target: n/a
Current: $21.07
Upside: -